Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 2/20 | 0.40 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568144 | 1.00 | POLB (0.49) | POLBCYP3A4CYP2D6FKBP1ALTA4H | |
| SCHEMBL2651732 | 1.00 | POLB (0.49) | POLBCYP3A4CYP2D6FKBP1ALTA4H | |
| SCHEMBL12886363 | 0.94 | FKBP1A (0.49) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL2616299 | 0.94 | FKBP1A (0.49) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL15316989 | 0.94 | FKBP1A (0.49) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29447337 | 0.92 | FKBP1A (0.48) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL2772253 | 0.87 | — | — | |
| SCHEMBL19165790 | 0.86 | POLB (0.52) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL19166211 | 0.86 | POLB (0.52) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 | |
| SCHEMBL19165735 | 0.86 | POLB (0.52) | POLBCYP3A4CYP2D6FKBP1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874118-A | Method for synthesizing N-methyl-D-prolinol by one-pot method | 重庆医药高等专科学校 | 2022-08-09 | — | — | CN | claimed |
| US-12187702-B2 | Sulfonamideurea compounds | INFLAZOME LIMITED (IE) | 2025-01-07 | — | — | US | disclosed |
| CN-114874118-A | Method for synthesizing N-methyl-D-prolinol by one-pot method | 重庆医药高等专科学校 | 2022-08-09 | — | — | CN | disclosed |
| CN-114874118-A | Method for synthesizing N-methyl-D-prolinol by one-pot method | 重庆医药高等专科学校 | 2022-08-09 | — | — | CN | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| CN-112672995-A | Novel sulfonamide urea compounds | 英夫拉索姆有限公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020035464-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| CN-1929836-A | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725232-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | disclosed |
| EP-1685102-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2006-08-02 | — | — | EP | disclosed |
| CN-1747930-A | Compounds having prolyl oligopeptidase inhibitory activity | ORION CORP (FI) | 2006-03-15 | — | — | CN | disclosed |
| WO-2005089754-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005047251-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | POLB 4648/4885CYP3A4 222/4885CYP2D6 394/4885 |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | POLB 4763/4885CYP3A4 737/4885CYP2D6 584/4885 |
| US-12187702-B2 | Sulfonamideurea compounds | NLRP3, NOD1, NLRP1 | POLB 4443/4885CYP3A4 137/4885CYP2D6 227/4885 |
| US-20070129346-A1 | Melanocortin receptor agonists | MC1R, MC3R, MC5R | POLB 4164/4885CYP3A4 1804/4885CYP2D6 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.